Tyr571

Site Information
PEELKRDyVDEQTGD SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 34360219

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 )
Disease tissue studied:	brain cancer ( 1 , 3 ) , glioblastoma ( 1 , 3 ) , glioma ( 1 , 3 )
Relevant cell line - cell type - tissue:	glial-brain ( 1 ) , Jurkat (T lymphocyte) ( 2 ) , M059K (glial) ( 3 )

References
1	Johnson H, White FM (2014) Quantitative analysis of signaling networks across differentially embedded tumors highlights interpatient heterogeneity in human glioblastoma. J Proteome Res 13, 4581-93 24927040 Curated Info
2	Zhou J (2012) CST Curation Set: 14432; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876 Curated Info
3	Stokes M (2007) CST Curation Set: 2265; Year: 2007; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info